Neogen Corp: Form 10-Q for the period ended Feb 29, 2024
Filed with the SEC on Apr 9, 2024 and accepted by EDGAR at Apr 9, 2024, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-02-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-12-01 to 2024-02-29 | $228.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-06-01 to 2024-02-29 | $687.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-12-01 to 2024-02-29 | $111.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-06-01 to 2024-02-29 | $337.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-12-01 to 2024-02-29 | $116.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-06-01 to 2024-02-29 | $350.4m | us-gaap:GrossProfit |
| Research and development | 3 months2023-12-01 to 2024-02-29 | $4.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-06-01 to 2024-02-29 | $17.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-12-01 to 2024-02-29 | $12.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-06-01 to 2024-02-29 | $45.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-12-01 to 2024-02-29 | $10.5m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-06-01 to 2024-02-29 | $31.4m | us-gaap:InterestExpense |
| Income tax | 3 months2023-12-01 to 2024-02-29 | −$3.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-06-01 to 2024-02-29 | −$3.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-12-01 to 2024-02-29 | −$2.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-06-01 to 2024-02-29 | −$4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-12-01 to 2024-02-29 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-06-01 to 2024-02-29 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-12-01 to 2024-02-29 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-06-01 to 2024-02-29 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-12-01 to 2024-02-29 | 216,597,777 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-06-01 to 2024-02-29 | 216,438,643 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-06-01 to 2024-02-29 | $8.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-06-01 to 2024-02-29 | $87.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-02-29 | $161.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-02-29 | $602.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-02-29 | $4.58bn | us-gaap:Assets |
| Current liabilities | At period end2024-02-29 | $157.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-02-29 | $1.44bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-02-29 | $887.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-02-29 | $2.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-02-29 | $3.15bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-02-29 | 216,607,746 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-24-042952. Last ingested by Listed: Oct 30, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.